Rockwell Medical (RMTI) Expected to Announce Quarterly Earnings on Thursday

Rockwell Medical (NASDAQ:RMTI) is anticipated to issue its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of $0.04 per share and revenue of $18.5820 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 26, 2026 at 8:00 AM ET.

Rockwell Medical Stock Performance

Shares of RMTI stock opened at $1.03 on Thursday. The stock has a market cap of $40.58 million, a PE ratio of -6.44 and a beta of 1.71. The stock has a 50-day moving average of $1.01 and a 200-day moving average of $1.08. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.91 and a quick ratio of 3.50. Rockwell Medical has a one year low of $0.78 and a one year high of $2.10.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of RMTI. XTX Topco Ltd lifted its position in Rockwell Medical by 286.5% during the 4th quarter. XTX Topco Ltd now owns 62,097 shares of the company’s stock worth $52,000 after buying an additional 46,029 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Rockwell Medical in the 4th quarter valued at about $84,000. Geode Capital Management LLC increased its position in shares of Rockwell Medical by 12.9% in the fourth quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock valued at $304,000 after acquiring an additional 41,668 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in Rockwell Medical by 12.3% during the third quarter. Vanguard Group Inc. now owns 1,354,147 shares of the company’s stock worth $1,625,000 after acquiring an additional 148,737 shares in the last quarter. Institutional investors own 23.31% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on RMTI shares. Weiss Ratings restated a “sell (d-)” rating on shares of Rockwell Medical in a report on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating and set a $2.50 target price on shares of Rockwell Medical in a report on Monday, January 26th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Rockwell Medical currently has an average rating of “Hold” and an average target price of $2.50.

Rockwell Medical Company Profile

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.